Hydroxocobalamin Conversion in Methylmalonic Acidemia

Introduction to Defects and Treatment

Individuals with methylmalonic acidemia due to cblA, cblB, and cblD variant 2 defects can convert hydroxocobalamin, but the conversion is impaired, requiring high-dose hydroxocobalamin therapy (milligram doses daily) 1, 2, 3
The American Society of Human Genetics/American College of Medical Genetics guidelines distinguish between patients with biosynthetic defects, who need dramatically higher doses, and those with simple malabsorption 1, 2, 3

The American College of Medical Genetics recommends using hydroxocobalamin (or methylcobalamin) rather than cyanocobalamin for patients with these defects, especially in patients with renal dysfunction 4
Monitoring efficacy should include urine or blood methylmalonic acid levels, clinical response (neurologic function, growth parameters), and adjustment of protein intake as tolerated 1, 2, 3, 5

Patients with methylmalonic acidemia show prompt biochemical improvement with intramuscular hydroxocobalamin administration, and most achieve moderate neurologic improvement with treatment, although methylmalonic acid levels improve but do not normalize 5
Even after liver transplantation, patients remain at risk for neurological deterioration and progressive renal insufficiency, indicating that complete metabolic correction is not achievable 5

The body generates two coenzymes from cobalamin: adenosylcobalamin serves as the cofactor for methylmalonyl-CoA mutase, while methylcobalamin is required for methionine synthase, with both forms following the same route of intracellular processing 6, 7, 8
In cobalamin deficiency states, methylmalonic acid accumulates due to insufficient adenosylcobalamin for methylmalonyl-CoA mutase, while homocysteine accumulates due to insufficient methylcobalamin for methionine synthase 6, 7